By Dr Melvin Teck Meng Chin

Journal articles

Taggart J; Chin M; Liauw W; Harris MF, 2024, 'Sharing Colorectal Cancer Follow-Up Using an E-Care Plan Between Cancer Services and Primary Health Care', Studies in Health Technology and Informatics, 310, pp. 1517 - 1518, http://dx.doi.org/10.3233/SHTI231272

Gray R; Chin M; Vickers D; Indraratna P; Cranney G; Mathur G; Chen D, 2024, 'Kiosk 9Q-FA-02 Utility of CMR in Diagnosis of Metastatic Cardiac Melanoma', Journal of Cardiovascular Magnetic Resonance, 26, pp. 100930, http://dx.doi.org/10.1016/j.jocmr.2024.100930

Newman B; Chin M; Robinson L; Chauhan A; Manias E; Wilson C; Harrison R, 2023, 'Improving Medication Safety in Cancer Services for Ethnic Minority Consumers: Protocol for a Pilot Feasibility and Acceptability Study of a Co-Designed Consumer Engagement Intervention', JMIR Research Protocols, 12, pp. e49902, http://dx.doi.org/10.2196/49902

Chauhan A; Newman B; Roberto E; Walpola RL; Seale H; Chin M; Harrison R, 2023, 'Making it Meaningful : Co-designing an intervention to improve medication safety for people from culturally and linguistically diverse backgrounds accessing cancer services', Patient Experience Journal, 10, pp. 34 - 48, http://dx.doi.org/10.35680/2372-0247.1732

Pitiyarachchi O; Wong W; Chin M, 2022, 'Durvalumab and multimodality therapy in a patient with multiple recurrent and unresectable cutaneous squamous cell carcinoma', Internal Medicine Journal, 52, pp. 1103 - 1104, http://dx.doi.org/10.1111/imj.15809

Harrison R; Chin M; Ni She E, 2022, 'What does co-design mean for Australia's diverse clinical workforce?', Australian Health Review, 46, pp. 60 - 61, http://dx.doi.org/10.1071/AH21116

Harrison R; Walton M; Manias E; Wilson C; Girgis A; Chin M; Leone D; Seale H; Smith AB; Chauhan A; Smith B; Walpola R, 2021, 'Codesigning consumer engagement strategies with ethnic minority consumers in Australian cancer services: The CanEngage Project protocol', BMJ Open, 11, pp. e048389, http://dx.doi.org/10.1136/bmjopen-2020-048389

Taggart J; Chin M; Liauw W; Goldstein D; Dolezal A; Plahn J; Harris MF, 2021, 'Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice', Public Health Research and Practice, 31, http://dx.doi.org/10.17061/PHRP31122108

McLean LS; Faisal W; Parakh S; Kao SC; Lewis CR; Chin MT; Voskoboynik M; Itchins MJ; Jennens RR; Broad AR; Morris TA; Solomon BJ, 2021, 'Standard-dose osimertinib in egfr-mutated non-small-cell lung adenocarcinoma with leptomeningeal disease', JCO Precision Oncology, 5, pp. 561 - 568, http://dx.doi.org/10.1200/PO.20.00464

Vuong K; Uebel K; Agaliotis M; Jun S; Taggart J; Suchy S; Liauw W; Chin M; Webber K; Harris M, 2020, 'Assessing suitability for long-term colorectal cancer shared care: a scenario-based qualitative study', BMC Family Practice, 21, pp. 240, http://dx.doi.org/10.1186/s12875-020-01311-w

Ali A; Dumbrava M; Riddell K; Stewart N; Ward R; Ibrahim AK; Chin M, 2020, 'Correlation between initial tumour volume and treatment duration on Dabrafenib: Observation study of subjects with BRAF mutant melanoma on the BRF112680 trial', BMC Cancer, 20, pp. 342, http://dx.doi.org/10.1186/s12885-020-06848-8

Taggart J; Chin M; Liauw W; Dolezal A; Plahn J; Harris MF, 2019, 'Development of an interactive, web-based shared care plan to facilitate the follow-up care of colorectal cancer patients', , http://dx.doi.org/10.21203/rs.2.13454/v2

Lamprell K; Chin M; Braithwaite J, 2019, '“Can I still get a tattoo?” Patients’ experiences across the clinical trajectory for metastatic melanoma: a dynamic narrative model of patient journey', Patient Experience Journal, 6, pp. 87 - 93, http://dx.doi.org/10.35680/2372-0247.1301

Long JC; Debono D; Williams R; Salisbury E; O'Neill S; Eykman E; Butler J; Rawson R; Phan-Thien KC; Thompson SR; Braithwaite J; Chin M; Taylor N, 2018, 'Using behaviour change and implementation science to address low referral rates in oncology', BMC Health Services Research, 18, pp. 904, http://dx.doi.org/10.1186/s12913-018-3653-1

Lamprell K; Chin M; Braithwaite J, 2018, 'The plot thickens: Archetypal narrative structure in the melanoma patient journey', Cogent Medicine, 5, pp. 1484053, http://dx.doi.org/10.1080/2331205x.2018.1484053

Liang R; Meiser B; Smith S; Kasparian NA; Lewis CR; Chin M; Long GV; Ward R; Menzies AM; Harris-Wai JN; Kaur R, 2017, 'Advanced cancer patients’ attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study', European Journal of Cancer Care, 26, http://dx.doi.org/10.1111/ecc.12600

Schütze H; Chin M; Weller D; Harris MF, 2017, 'Patient, general practitioner and oncologist views regarding long-term cancer shared care.', Fam Pract, 35, pp. 323 - 329, http://dx.doi.org/10.1093/fampra/cmx105

Pianta TJ; Pickering JW; Succar L; Chin M; Davidson T; Buckley NA; Mohamed F; Endre ZH; Abdul Cader MF, 2017, 'Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy', Kidney and Blood Pressure Research, 42, pp. 62 - 75, http://dx.doi.org/10.1159/000469715

Sandler CX; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; segelov E; Boyle FM; Chin MT; webber K; Barry BK; Lloyd AR, 2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015

Lemech CR; Williams R; Thompson SR; McCaughan B; Chin M, 2016, 'Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: A case report', BMC Research Notes, 9, pp. 386, http://dx.doi.org/10.1186/s13104-016-2189-x

Bloem LT; De Abreu Lourenço R; Chin M; Ly B; Haas M, 2016, 'Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer', Oncology and Therapy, 4, pp. 103 - 116, http://dx.doi.org/10.1007/s40487-016-0020-4

He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL, 2016, 'The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study', ONCOLOGIST, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530

He EYJ; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL, 2016, 'The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: An Australian population-based multicenter study', Oncologist, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530

Taylor N; Long JC; Debono D; Williams R; Salisbury E; O'Neill S; Eykman E; Braithwaite J; Chin M, 2016, 'Achieving behaviour change for detection of Lynch syndrome using the Theoretical Domains Framework Implementation (TDFI) approach: A study protocol', BMC Health Services Research, 16, pp. 89, http://dx.doi.org/10.1186/s12913-016-1331-8

Au L; Grant M; Haydon A; Oliva K; Wilkins S; Segelov E; Antill Y; Peter C; Ranchod P; Polglase A; Chin M; Chip F; Skinner S; Roger W; McMurrick P; Shapiro J, 2016, '198P Use of chemotherapy and mismatch repair deficiency testing in resected stage II colon cancer', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw581.031

Sandler C; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; Segelov E; Boyle FM; Chin MTM; Barry BK; Webber K; Lloyd AR, 2015, 'TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.', Journal of Clinical Oncology, 33, pp. 9571 - 9571, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9571

Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau HT; Brown MP; Hamid O; Infante JR; Millward M; Pavlick A; Chin MT; O'Day SJ; Blackman SC; Martin C; Lebowitz P; Ma B; Ouellet D; Kefford RF, 2014, 'Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)', Clinical Cancer Research, 20, pp. 4449 - 4458, http://dx.doi.org/10.1158/1078-0432.CCR-14-0887

Mak G; Chin M; Nahar N; De Souza P, 2014, 'Cutaneous metastasis of prostate carcinoma treated with radiotherapy: A case presentation', BMC Research Notes, 7, pp. 505, http://dx.doi.org/10.1186/1756-0500-7-505

Mak G; Arkenau HT; Chin M, 2014, 'Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment', Melanoma Research, 24, pp. 408 - 412, http://dx.doi.org/10.1097/CMR.0000000000000085

Chin M; Ward RL, 2014, 'Targeting treatment for colorectal cancer: The EGFR antibody story', Cancer Forum, 38, pp. 39 - 43

Pianta T; Chin M; Peake P; Buckley N; Pickering J; Endre Z, 2013, 'PLASMA CYSTATIN C IS ELEVATED IN THE ABSENCE OF ACUTE KIDNEY INJURY FOLLOWING CISPLATIN WITH CONTEMPORARY ANTIEMETICS', NEPHROLOGY, 18, pp. 41 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323453000103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mak G; Ward R; Shehabi Y; Venkateswaran R; Chin M, 2013, 'Use of neostigmine in capecitabine-induced paralytic ileus', Tumori, 99, http://dx.doi.org/10.1177/030089161309900518

Mak G; Ward R; Shehabi Y; Venkateswaran R; Chin M, 2013, 'Use of neostigmine in capecitabine-induced paralytic ileus', Tumori Journal, 99, pp. e225 - e228, http://dx.doi.org/10.1177/030089161309900518

Lemech CR; Fontela A; Arkenau H-T; Chin MTM; Li S; Liauw WS; Thomas D; De Souza PL, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585

Pourgholami MH; Szwajcer M; Chin M; Liauw W; Seef J; Galettis P; Morris DL; Links M, 2010, 'Phase i clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer', Cancer Chemotherapy and Pharmacology, 65, pp. 597 - 605, http://dx.doi.org/10.1007/s00280-009-1157-8

Pourgholami MH; Szwajcer ; Chin MTM; Liauw WS; Szwajcer ; Galettis P; Morris DL; Links MJ, 2010, 'Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer', Cancer Chemotherapy and Pharmacology, 65, pp. 597 - 605, http://dx.doi.org/10.107/s00280-009-1157-8

Pearson S; Chin M; Faedo M; Ward RL, 2010, 'Rationale for treatment durations of targeted cancer agents', Lancet Oncology, 11, pp. 1113 - 1115, http://dx.doi.org/10.1016/S1470-2045(10

Grimison PS; T Chin M; Harrison ML; Goldstein D; Chin M, 2006, 'Primary pancreatic lymphoma - pancreatic tumours that are potentially curable without resection, a retrospective review of four cases', BMC Cancer, 6, pp. 117, http://dx.doi.org/10.1186/1471-2407-6-117

Wierzbicki AS; Reynolds TM; Crook MA; Tatler J; Peters BS; McBride M; Chin MTM; Lee SM; Kelly B, 1998, 'Lipid lowering therapy in patients with HIV infection (multiple letters) [3]', Lancet, 352, pp. 1782 - 1783, http://dx.doi.org/10.1016/s0140-6736(05)79858-5

Back to profile page